Ergotamine tartrate (sublingual tablet): Difference between revisions

Ergotamine tartrate (sublingual tablet)
Clinical data
Routes of; administration	Oral
ATC code	N02CA02 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only) ; UK: POM (Prescription only) ; US: ℞-only ;
Pharmacokinetic data
Metabolism	hepatic
Excretion	renal
Identifiers
	IUPAC name Ergotaman-3',6',18-trione, 12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'-alpha)- (9CI);
CAS Number	113-15-5;
PubChem CID	9787;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C33H35N5O5
Molar mass	581.66 g/mol

VisualWikitext

Revision as of 22:17, 11 February 2014

Ergotamine
ERGOMAR (ergotamine tartrate) tablet^® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Medihaler ergotamine (ergotamine tartrate) aerosol, metered^® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Medihaler ergotamine (ergotamine tartrate) aerosol, metered
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Pratik Bahekar, MBBS [2]

For patient information about Ergotamine, click here.

Synonyms / Brand Names:

Overview

Ergotamine is an ergopeptine and part of the ergot family of alkaloids; it is structurally and biochemically closely related to ergoline. It possesses structural similarity to several neurotransmitters, and has biological activity as a vasoconstrictor. It is used medicinally for migraine prevention (sometimes in combination with caffeine), and to induce childbirth and prevent post-partum haemorrhage.

FDA Package Insert

ERGOMAR (ergotamine tartrate) tablet

Medihaler ergotamine (ergotamine tartrate)

Mechanism of action

The mechanism of action of ergotamine is complex. The molecule shares similarity with neurotransmitters such as serotonin, dopamine, and adrenaline and can thus bind to several cell receptors acting both as agonist and antagonist in signal transduction within cellular tissues. The anti-migraine effect is due to constriction of the intercranial extracerebral blood vessels through the 5-HT_1B receptor, and by inhibiting trigeminal neurotransmission by 5-HT_1D receptors. Ergotamine also has effects on the dopamine and noradrenaline receptors. It is its action on the D2 dopamine and 5-HT_1A receptors that can cause some side effects. ^[1]

Biosynthesis

Ergotamine is a secondary metabolite (natural product) and the principal alkaloid produced by the ergot fungus, Claviceps purpurea, and related fungi in the family Clavicipitaceae. Its biosynthesis in these fungi requires the amino acid, L-tryptophan, and dimethylallyl diphosphate. These precursor compounds are the substrates for the enzyme, dimethylally-tryptophan (DMAT) synthase, catalyzing the first step in ergot alkaloid biosynthesis, i.e., the prenylation of L-tryptophan. Further reactions, involving methyltransferase and oxygenase enzymes, yield the ergoline, lysergic acid. Lysergic acid (LA) is the substrate of lysergyl peptide synthetase, a nonribosomal peptide synthetase, which covalently links LA to the amino acids, L-alanine, L-proline, and L-phenylalanine. Enzyme-catalyzed or spontaneous cyclizations, oxygenations/oxidations, and isomerizations at selected residues precede, and give rise to, formation of ergotamine.^[2]

Illegal uses

Ergotamine is also a precursor of LSD, lysergic acid diethylamide.

References

↑ Tfelt-Hansen P, Saxena PR, Dahlof C, Pascual J, Lainez M, Henry P, Diener H, Schoenen J, Ferrari MD, Goadsby PJ (2000). "Ergotamine in the acute treatment of migraine: a review and European consensus". Brain. 123: 9–18. PMID 10611116.
↑ Schardl CL, Panaccione DG, Tudzynski P (2006). "Ergot alkaloids--biology and molecular biology". Alkaloids Chem. Biol. 63: 45–86. PMID 17133714.
↑ ^3.0 ^3.1 caffeine."ERGOMAR (ERGOTAMINE TARTRATE) TABLET, ORALLY DISINTEGRATING [ROSEDALE THERAPEUTICS]".

Template:Antimigraine preparations

da:Ergotamin de:Ergotamin nl:Ergotamine sv:Ergotamin

Template:WikiDoc Sources

[Tfelt-1] Tfelt-Hansen P, Saxena PR, Dahlof C, Pascual J, Lainez M, Henry P, Diener H, Schoenen J, Ferrari MD, Goadsby PJ (2000). "Ergotamine in the acute treatment of migraine: a review and European consensus". Brain. 123: 9–18. PMID 10611116.

[Schardl-2] Schardl CL, Panaccione DG, Tudzynski P (2006). "Ergot alkaloids--biology and molecular biology". Alkaloids Chem. Biol. 63: 45–86. PMID 17133714.

[dailymed.nlm.nih.gov-3] 3.0 ^3.1 caffeine."ERGOMAR (ERGOTAMINE TARTRATE) TABLET, ORALLY DISINTEGRATING [ROSEDALE THERAPEUTICS]".

[1]

[2]

[3]

@@ Line 84: / Line 84: @@
 ==See also==
-* [[Cafergot]], a preventative migraine treatment with ergotamine and [[caffeine]].
+* [[Cafergot]], a preventative migraine treatment with ergotamine and <ref name="dailymed.nlm.nih.gov">[[caffeine]].{{Cite web  | last =  | first =  | title = ERGOMAR (ERGOTAMINE TARTRATE) TABLET, ORALLY DISINTEGRATING [ROSEDALE THERAPEUTICS] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1bfd4827-5123-4dbb-8f94-7b097f5bfd5c | publisher =  | date =  | accessdate = }}</ref> <ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = MEDIHALER ERGOTAMINE (ERGOTAMINE TARTRATE) AEROSOL, METERED [3M RIKER] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e713859d-f454-4f7e-a535-868b8d5f2c88 | publisher =  | date =  | accessdate = }}</ref>   Normal  0          false  false  false    EN-US  X-NONE  X-NONE
 ==References==